Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
직원
82
국가
US
ISIN
US68236R1032
상장
0 Comments
생각을 공유하기
FAQ
오늘 온코러스 (Oncorus) 주가는 얼마인가요?▼
ONCR의 현재 가격은 $0.13 USD이며, 지난 24시간 동안 -3.08% 하락했습니다. 차트에서 온코러스 (Oncorus) 주가 흐름을 자세히 살펴보세요.
온코러스 (Oncorus)의 주식 심볼은 무엇인가요?▼
거래소에 따라 주식 심볼이 다를 수 있습니다. 예를 들어, 거래소에서는 온코러스 (Oncorus) 주식이 ONCR 심볼로 거래됩니다.